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9Abstract
Th e possible carcinogenic risk of immunosuppressive therapies is an im-
portant issue in everyday clinical practice. Carcinogenesis is a slow multi-
step procedure and there is a long latency period before cancer develops. 
PUVA is an acronym from psoralen plus UVA. PUVA regimens can be di-
vided into systemic PUVA or topical PUVA according to the administra-
tion route (oral or topical). PUVA can be used in many skin diseases in-
cluding psoriasis, early stage mycosis fungoides, atopic dermatitis, palmo-
plantar pustulosis and chronic eczema. Systemic PUVA therapy has previ-
ously been associated with an increased risk on nonmelanoma skin cancer 
and especially squamous cell carcinoma (SCC). Th e increased risk of ba-
sal cell carcinoma (BCC) is also documented but it is modest compared 
to SCC. Most concern has been about the increased melanoma risk that 
might be associated to systemic PUVA therapy.
Th is study evaluated melanoma and noncutaneous cancer risk associ-
ated with systemic PUVA, and the persistence of nonmelanoma skin can-
cer risk aft er systemic PUVA treatment is stopped. In addition, develop-
ment of subsequent cancer in cutaneous T cell lymphoma patients (CTCL) 
as a possible side eff ect of PUVA in immunocompromized persons was 
studied. Th e possible cancer risk related to usage of an immunosuppres-
sive drug, cyclosporine, in diff erent infl ammatory skin diseases was also 
monitored.
Th e fi rst three studies are part of an American PUVA follow-up cohort 
of 1380 psoriasis patients. Th e risk of melanoma started to increase 15 
years aft er the fi rst treatment with systemic PUVA. Th e risk was highest 
among persons who had received over 250 treatments. In noncutaneous 
cancer, the overall risk was not increased (RR=1.08, 95% CI= 0.93–1.24), 
but signifi cant increases in risk were found in thyroid cancer, breast can-
cer and in central nervous system neoplasms. Th ere was no association 
between higher PUVA levels and these cancers. Th e increased risk of SCC 
was associated to high cumulative UVA exposure in the systemic PUVA 
regimen and remained high even among patients with little exposure to 
systemic PUVA during recent years. Th e patients with high risk had no 
substantial exposure to other carcinogens. In BCC there was a similar but 
more modest tendency.
In the two other studies, the patients were from the database of the 
Finnish Cancer Registry and Department of Dermatology, Helsinki Uni-
versity Central Hospital. CTCL patients are commonly treated with PUVA. 
In a cohort of 319 patients, the risk of all secondary cancers (SIR) in CTCL 
Abstract
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patients was 1.4 (95% CI=1.0–1.9). In separate sites, the risk of lung cancer, 
Hodgkin and non-Hodgkin lymphomas were increased. PUVA seemed not 
to contribute to any extent to the appearance of these cancers in contrast to 
psoriasis patients. Th e carcinogenity of short term cyclosporine was evalu-
ated in 272 patients with infl ammatory skin disease. We did not detect 
increase in the risk of skin malignancies or overall risk of cancer.
In conclusion, long term use of systemic PUVA therapy increased the 
risk of malignant melanoma. It did not aff ect the risk of noncutaneous can-
cers but was connected with a persistent risk for the development of non-
melanoma skin cancer. In CTCL patients, PUVA treatment did not con-
tribute to the development of secondary cancers. Th ere was no evidence 
that short term cyclosporine treatment is a major risk factor for develop-
ment of subsequent malignancy. Our studies confi rm the increased skin 
cancer risk related to PUVA treatment in psoriasis patients. In other in-
fl ammatory skin diseases (atopic dermatitis, palmoplantar pustulosis and 
chronic hand eczema) low dose, short-term cyclosporine treatment seems 
to be without major risk. 
Abstract
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Introduction
When conventional topical treatments have failed or are not effi  cient, im-
munosuppressive therapy may be considered in skin diseases. Th ese thera-
pies may include photochemotherapies such as PUVA or systemic drugs 
such as cyclosporine. Th ese treatments have improved the quality of life 
in many skin disease patients, but adverse eff ects may appear. Cutaneous 
carcinogenesis is a long-term multistep process. Th erefore, to evaluate the 
causative factors of skin cancer epidemiological studies with long follow-
up times must be performed. UV exposure may take over 20 years to pro-
duce skin cancer. Immunosuppressive treatments carry a risk of squamous 
cell carcinoma (SCC) in psoriasis patients (Stern et al., 1988; Lindelöf et al., 
1991), but there are few reports of non-cutaneous cancers related to these 
immunosuppressive treatments. Fortunately, SCC is less harmful com-
pared to melanoma. Psoriasis patients are oft en treated with other poten-
tially carcinogenic treatments, thus the adverse eff ect caused by an individ-
ual treatment may be diffi  cult to estimate. Th e risk of systemic PUVA treat-
ment has been mainly investigated with psoriasis patients. CTCL patients 
are in the early phase also treated with PUVA, but there are no studies on 
the eff ects of PUVA treatment in this group.
Cyclosporine is an eff ective treatment in infl ammatory skin diseases. 
Th e carcinogenic information comes mainly from epidemiological studies 
made in organ transplant patients. Th ere are two studies evaluating the 
relative risk of malignancy related to cyclosporine use in psoriasis patients 
(Marcil and Stern, 2001; Paul et al., 2003). In other skin diseases there are 
no previous studies concerning the risk of cyclosporine to the develop-
ment of later cancers. 
In the PUVA follow-up study, we have investigated the risk of melan-
oma, noncutaneous cancer and SCC and BCC in psoriasis patients. In 
further studies the infl uence of photochemothrapy to the development of 
secondary cancers in CTCL and the role of cyclosporine in later cancer 
development in infl ammatory skin diseases were evaluated.
Introduction
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Review of the literature
Infl ammatory skin diseases commonly treated with 
photochemotherapy
Psoriasis
Psoriasis is a chronic infl ammatory skin disease and its prevalence is 
around two per cent in various population-based studies (Lomholt, 1964; 
Farber and Nall 1998). Psoriasis has a clear genetic susceptibility, although 
the inheritance pattern is still unclear (Henseler and Christophers, 1985). 
Th e recent genetic studies have revealed major locus on chromosome 6 
(Asumalahti et al., 2002). However, it is assumed that several genes aff ect 
the pathogenesis of psoriasis. Other psoriasis susceptibility loci are found 
in chromosomes 1, 3, 4, 16, 17, 19 (Matthews et al., 1996; Nair et al., 1997; 
Lee et al., 2000a; Veal et al., 2001; Karason et al., 2005).
Clinically psoriasis presents as a well-demarcated, hyperkeratotic pla-
ques, which favours knees, elbows, lumbar area and scalp (Braun-Falco, 
2000). Th e disease has two peaks of onset: at young adulthood and at mid-
dle age. Various environmental factors including infections are well known 
triggers for psoriasis (Schön and Boehncke, 2005). Th e severity of psoriasis 
has clear seasonal variation. Sun exposure is oft en benefi cial, but exten-
sive sunburn can trigger or worsen the lesions. Streptococcal infection can 
elicit a typical guttate type-psoriasis eruption. Physical trauma can trig-
ger psoriasis to otherwise healthy-looking skin. A few drugs, such as beta-
blockers, lithium and interferon-alpha, are able to exacerbate psoriasis. 
Th e mechanism of these events is unclear, but some of them are probably 
related to cytokine release and unmasking of autoantigens.
Histopathologically psoriasis plaques include hyperproliferation of ke-
ratinocytes and hyperkeratosis combined with infl ammatory cell infi ltra-
tion (Weedon, 2002; McKee, 2005). 
Th e primary pathogenetic mechanism of psoriasis is not known. Cur-
rently, psoriasis is recognized as a T cell mediated immune disease.Th e 
epidermal hyperplasia is due to activation of the immune system, which is 
mediated by accumulating T lymphocytes in the skin. An unknown anti-
gen is taken up by Langerhans cells (LCs) and presented to T lymphocytes 
in lymph nodes. Eventually, this leads to diff erentiation of T cells and fi -
nally the secretion of proinfl ammatory cytokines such as IL–1, gamma in-
terferon, IL–6 (Krueger, 2002; Schön and Boehncke, 2005). Recently, an 
interesting study related to the pathogenesis of psoriasis was published. 
Epidermal keratinocytes express JunB, a gene, which regulates cell prolif-
Review of the literature
13
eration and diff erentiation responses (Shaulian and Karin, 2002). Zenz et 
al. have shown that the expression of this gene is reduced in psoriatic skin. 
In mice, they showed that deletion of this protein resulted a phenotype 
resembling psoriasis. Th e deletion of this protein in keratinocytes triggers 
the expression of cytokines (e.g. tumor necrosis factor alpha, gamma in-
terferon, IL–2, IL–6, IL–8) and chemokines (Zenz et al., 2005), which can 
together with adhesion molecules recruit tissue specifi c lymphocytes into 
psoriasis plaques.
Mild psoriasis is treated with topical corticosteroids, anthralin, tar, cal-
citriol or calcipotriol. Phototherapy regimens used in psoriasis are UVB 
(broad- and narrow-band UVB), SUP (only in children) and PUVA (psor-
alen + UVA) (Ortel and Höningsmann, 1999). PUVA treatment is divided 
into systemic PUVA and topical PUVA according to the administration 
route. Systemic PUVA includes oral intake of psoralen tablets and topi-
cally psoralens can be applicated as ointments or bath water. Phototherapy 
regimens belong to the treatment armamentarium of moderate to severe 
psoriasis (i.e., 10–25% of body surface area). Widespread, eruptive and 
relatively superfi cial forms of psoriasis respond well to UVB treatment. 
Treatment is usually administered three times a week and the clearance 
takes 25 treatments in majority of cases (Stern, 1997). All forms of psoria-
sis, excluding generalized pustular psoriasis and erythrodermic psoriasis, 
respond well to PUVA treatment, but it is mostly used in plaque-type pso-
riasis. PUVA treatment is considered to be more eff ective than broadband 
UVB in the treatment of psoriasis (Ortel and Höningsmann, 1999), how-
ever narrow-band UVB is as eff ective as bath-PUVA (Dawe et al., 2003; 
Snellman et al., 2004). Cyclosporine and methotrexate are used in psoriasis 
if there is no satisfactory response to phototherapy or it is contraindicated. 
Low-dose methotrexate is highly eff ective in psoriatic arthritis. Oral retin-
oid acitretin can be combined with phototherapies. During the last few 
years, biological treatments have been introduced to treatment for most 
severe psoriasis cases.
Atopic dermatitis
Atopic dermatitis (atopic eczema) is determined as an itchy, infl ammatory 
skin condition. Th e predilection sites are the skin fl exures in childhood, 
but in adults it usually aff ects face, neck and upper part of the torso. Clini-
cally it is a poorly defi ned erythema. In the acute phase the skin presents 
oedema, vesicles and weeping and the chronic stage can lead to skin thick-
ening (lichenifi cation) (Williams, 2005). Although atopic constitution is 
characterized by a tendency to produce IgE as a response to allergens, 
40–60% of patients with atopic dermatitis do not have demonstrable IgE 
mediated hypersensivity (Flohr et al., 2004). Th e incidence of atopic der-
matitis is highest in Scandinavia, the United Kingdom and in the United 
States (ISAAC, 1998). 
Infl ammatory skin diseases commonly treated with photochemotherapy
14
Th e histologic features of atopic dermatitis include epidermal hyperpla-
sia, spongiosis, thickening of the papillary dermis, and a perivascular infi l-
trate consisting of monocytes, T cells and APC’s. (MacKee et al., 2005).
Atopic dermatitis has a familiar occurrence and genetic studies have 
linked this disease to polymorphic loci in chromosomes 1,3,5 and 11 
(Cookson et al., 1992; Cookson, 1998; Lee et al., 2000; Cookson et al., 2001; 
Tsunemi et al., 2002).
Typical features of atopic dermatitis include a reduced barrier function 
of the skin, which permits environmental antigens, such as pollen, house 
dust mite and staphylococcal enterotoxins to enter the skin. Th ese com-
pounds are bound to antigen-presenting cells via IgE and the high-affi  nity 
Fc epsilon receptors. Th e epsilon Fc receptors are abundant in the atopic 
skin. Antigen presenting cells in the atopic skin include the Langerhans 
cells and infl ammatory dendritic epidermal cells (IDEC). Th e IDECs are 
mainly seen during the acute infl ammation. Th e dendritic cells present the 
processed antigens to the T cells, which proliferate and cause mainly the 
clinical symptoms of atopic dermatitis. Another pathway is the direct stim-
ulation of the T cells by staphylococcal enterotoxins which is independ-
ent of IgE. Th erefore the enterotoxins are called “superantigens” (Leung D, 
2000; Novak et al. 2003). Aft er antigen presentation the T cells diff erentiate 
into Th 1 or Th 2 cells. Th e Th 1 response is associated with delayed-type 
hypersensitivity with release of IFN-gamma and IL-2, whereas the Th 2 re-
sponse is related to IgE mediated reaction with the predominance of IL-4, 
IL-5, IL-13 (van der Heijden et al., 1991; Grewe et al., 1994; Novak et al., 
2003). Following repeated contact with the same antigen keratinocytes re-
lease cytokines (IL-1 and TNF-alfa) inducing expression of adhesion mol-
ecules (Köck et al., 1990), which further allure T cells to the location. In 
acute atopic dermatitis the lesions express the Th 2 cytokine profi le whereas 
in chronic lesions the profi le looks more like Th 1 type.
In atopic eczema, the standard treatment has included topical corticos-
teroid emollients until recently, when also topical calcineurin inhibitors 
(tacrolimus and pimecrolimus) have been shown to be eff ective (Ashcroft  
et al., 2005). Broad- and narrowband UVB and selective ultraviolet pho-
therapy (SUP) are eff ective treatments in atopic dermatitis. Th ese treat-
ments are usually given three times a week over a period of 15–20 treat-
ments. In chronic atopic dermatitis SUP (UVA/UVB) treatment is found to 
be more eff ective compared to broadband UVB therapy (Jekler and Larkö, 
1990). Th e use of systemic cyclosporine is restricted to patients who do not 
respond to other conventional treatments.
Palmoplantar pustulosis
Palmoplantar pustulosis (PPP) is a common chronic skin disease where 
the lesions are restricted to the palms and soles. Patients may have psoria-
sis-like lesions on their forearms and legs, but the relationship to psoria-
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sis is controversial. Women are more oft en aff ected than men. Th e disease 
is more common among smokers (Eriksson et al., 1998). Clinically PPP 
presents as small 1–5 mm size fresh pustules, dry yellowish lesions and 
accumulations of crust and scale. Th ese intraepidermal pustules are ster-
ile. Histologically the lesions show vesicles surrounded by neutrophils. Th e 
dermis has only mild infl ammation (Braun-Falco, 2000).
Treatment options in palmoplantar pustulosis include topical treatment 
with corticosteroids, topical PUVA treatment, tetracyclines, methotrexate, 
acitretin and cyclosporine. 
Chronic hand eczema
Eczema is a clinically and histologically defi ned pattern of skin infl am-
mation, which can etiologically be divided into endogenous or exogenous 
forms. Th e exogenous form is further divided into irritant or allergic con-
tact eczema depending on the mechanism by which the exogenous agent 
initiates the reaction. Clinically it is impossible to make a distinction be-
tween etiologic factors. Hand eczema shows redness, scaling, and also 
small papulovesicles. 
Chronic hand eczema is treated in a very similar way to atopic eczema. 
Topical corticosteroid treatments, UVB irradiation localised to hands and 
topical PUVA treatments are used. Cyclosporine is used for therapy resist-
ant cases.
Skin-associated malignancies treated with 
photochemotherapy
Cutaneous T cell lymphomas
Th e European Organization for Research and Treatment of Cancer 
(EORTC) Cutaneous Lymphoma Project Group recently published new 
criteria for CTCL classifi cation (Willemze et al., 1997; Willenze et al., 2005). 
Th e two most common forms of CTCL are mycosis fungoides, which com-
prises one half of all CTCLs, and Sezary´s syndrome. Mycosis fungoides 
can be defi ned as a clonal proliferation of skin infi ltrating T lymphocytes 
(Diamandidou et al., 1996). Th ese T lymphocytes are small or medium-
sized cells with cerebriform nuclei. Clinically the lesions oft en fi rst present 
on the trunk and buttocks. In the patch stage the lesions may resemble 
psoriasis presenting as red-violet, oval, round, serpiginous plaques. In the 
infi ltrative stage the lesions become indurated plaques, but there is usually 
no lymph node involvement. In the more advanced tumor stage, the le-
sions enlarge, become ulcerated and invasion to internal organs may occur 
(Souhami and Tobias, 2005; Willemze et al., 2005). Today mycosis fun-
goides is classifi ed according to lymph node involvement and invasiveness 
(Willemze et al., 2005).
Skin-associated malignancies treated with photochemotherapy
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Th e prognosis of mycosis fungoides patients is dependent on the stage 
and the type of skin lesions and the presence of extracutaneous disease. If 
a patient has a limited patch or plaque stage mycosis fungoides, the life ex-
pectancy does not diff er from age-, sex-, and race-matched control popula-
tion (Willemze et al., 2005). Sezary´s syndrome is the erythrodermic and 
leukemic variant of CTCL. Lymph node enlargement and hepatomegalia 
are common features. In the peripheral blood there are typical Sezary´s 
cells, which are atypical lymphocytes with cerebriform nuclei (Weedon, 
2000). Sezary´s syndrome has a poor prognosis with 5-year survival of 11 
% (Willemze et al., 1997).
Th e specifi c chromosomal translocations for MF have not been identi-
fi ed. In most cases there are clonal T cell receptor gene rearrangements. 
Many structural and numerical chromosomal abnormalities have been de-
tected (Karenko et al., 1997; Smoller et al., 2003).
Histolopathologically early mycosis fungoides may be diffi  cult to di-
agnose. Th e classical histologic features include upper dermal infi ltrate 
with atypical lymphocytes, the number of which can be sparse in the early 
phases. Th e malignant cerebriform lymphocytes typically infi ltrate to epi-
dermis and form Pautrier microabscesses. As the disease progresses to 
tumour stage and systemic involvement, the epidermotrophism decreases 
(McKee, 2005).
CTCL confi ned to the skin (early stage mycosis fungoides) is treated 
with photo(chemo)therapy: UVB irradiation and PUVA (Whittaker et al., 
2003; Drummer et al., 2003). For small, limited patch stage lesions topical 
corticosteroids are a good choice.
Human skin
Th e human skin can be divided into two diff erent layers: the epidermis 
and the dermis. Th e epidermis is composed of four diff erent cell types: 
keratinocytes, melanocytes, Langerhans’ cells and Mercel’s cells. Th e most 
superfi cial part of the epidermis is stratum corneum, which is comprised 
of dead, dry cells and it has a fi lter function. Stratum corneum is biochemi-
cally composed of keratin proteins, transglutaminases, free amino acids 
and other compounds, which can bind water. 
LCs belong to a family of antigen presenting cells. In skin, they are lo-
cated in the basal and suprabasal layers of the epidermis. During contact 
hypersensitivity induction, the role of LCs is to present antigen-specifi c 
signals to T cells, as previously described. Keratinocytes are the main cell 
type of epidermis. Th ey are mainly responsible for the production of kerat-
ins. Keratinocytes also produce infl ammatory mediators that are essen-
tial in infl ammatory skin diseases. Melanocytes are located between basal 
cell keratinocytes in the basal layer of the epidermis. Th e main function 
Review of the literature
17
of melanocytes is to synthesize melanin, but they also express various cy-
tokines.
Th e skin is classifi ed into diff erent types according to its erythema re-
sponse and ability to tan. Th is Fitzpatrick classifi cation divides skin to 
types I–VI (Fitzpatrick, 1988). Skin types I–IV are used in white people 
and types V–VI in dark skinned or black people. People in skin types I–II 
always or easily sunburn and tan with diffi  culty, if ever. People with skin 
types III–IV always tan and burn minimally. In Finland about 60% of peo-
ple are of skin type III and 25% of skin type II (Jansen, 1989). Skin cancer 
is most common in types I–II.
UV radiation
The physical properties of UV radiation
UV radiation is electromagnetic radiation. Th e electromagnetic spectrum 
of light is presented in Figure 1. Th e wavelength of UV radiation lies just 
below visible light.
Figure 1 Th e Electromagnetic Spectrum
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UV radiation can be classifi ed artifi cially, according to wavelength, 
into three diff erent categories: UVC (200–280 nm), UVB (280–320 nm) 
and UVA (320–400 nm). Th e UVA region is further divided into UVA1 
(340–400 nm) and UVA2 (320–340 nm). Th e ozone layer blocks wave-
lengths shorter than 290 nm and thus, in addition to UVC, also part of 
UVB radiation. On earth, both UVA and UVB reach the surface at signifi -
cant amounts to be able to infl uence biological events on the skin. Five per 
cent all UV radiation reaching the earth is of UVB radiation and 95% is of 
UVA radiation. UVA radiation passes through windows. In vitro, UVC is 
a potent mutagen (Evans et al., 1997), and it is used for sterilization and 
disinfection purposes. 
Th e depth of penetration of UV radiation depends on the wavelength: 
the longer wavelengths have the capacity to penetrate deeper than shorter 
ones. Most of the UVB radiation is absorbed to the stratum corneum and 
epidermis and only 5–10% can reach basal keratinocytes, and dermis. In 
diff erent studies 19–50% of solar UVA can reach the depth of melanocytes, 
whereas only 9–14% of UVB reaches that level (Kaidbey et al., 1979; Bruls 
et al., 1984). Fift y per cent of UVA radiation respectively is absorbed to the 
stratum corneum and epidermis, but the rest penetrates deeply into the 
dermis (Parrish, 1983; Bruls et al., 1984). 
Radiometric units used in measuring the UV irradiation and its interac-
tions with skin are energy, power, irradiance and exposure dose. Energy is 
the work or potential of irradiation and it is expressed in joules (J). Power 
is the rate at which irradiation is expended and is measured in watts (W= 
J/s). Irradiance is expressed in W/cm2 and the exposure dose is obtained by 
multiplying irradiance with exposure time.
The biological effects of UV radiation
Erythema, skin reddening, is a result of increased blood fl ow in the super-
fi cial parts of the dermis. It is caused by the direct eff ect of UV radiation to 
the blood capillaries but also through chemical mediators (e.g., histamine, 
cytokines, prostaglandins) (Soter, 1993). Th e minimal erythemal dose 
(MED) is the unit used to determine the ability of UV radiation to induce 
erythema: it is the lowest UV dose needed to induce weak pink erythema 
on the skin. Th e eff ectiveness of radiation to induce erythema of diff erent 
wavelengths is called the erythema action spectrum. Shorter wavelengths 
are the most erythematogenic. Th us both UVB and UVA radiation are ca-
pable of inducing erythema to the skin, but UVB radiation is about 1000 
times more potent than UVA. UVB radiation is more effi  cient in induc-
ing sunburn (McKinlay and Diff ey, 1987). UVB mediated damage of ke-
ratinocytes results in the formation of sunburn cells (Schwarz et al., 1995). 
Th ese cells have suff ered from signifi cant DNA damage and are eliminated 
through apoptosis. UVA radiation is much more potent in inducing imme-
diate and persistent pigment darkening (Irwin, 1993; Wang, 2001).
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Environmental factors affecting UV radiation
Ozone is formed by UV radiation and oxygen and it acts as earth’s natural 
sunscreen. As a consequence of ozone depletion increased levels of UVB 
and even UVC reach on the earth’s surface. Of special concern is the in-
creased UVB radiation, since ozone depletion increases the most carcino-
genic part of UV radiation to reach the earths surface. Th e ozone layer has 
decreased by 2% during the last 20 years (Armstrong and Kricker, 1995). 
Some studies estimate that a 1% decrease in ozone concentrations will re-
sult approximately in a 3,5% squamous cell carcinoma (SCC) increase and 
a 2,1% basal cell carcinoma (BCC) increase (Diff ey, 1999). In Australia low 
ozone values has been detected possibly as a refl ection of Antarctic ozone 
depletion (Diff ey, 1999).
Th e latitudinal and altitudinal levels aff ect the amount of UV exposure. 
Th e incidence of SCC in white populations increases with proximity to the 
equator (Salari and Persaud, 2005).
UV radiation and cutaneous carcinogenesis
Chromophores and DNA damage
To begin a series of photochemical reactions and photobiological events 
possibly resulting in skin cancer, UV light must fi rst be absorbed by a 
chromophore. Each chromophore has a characteristic UV radiation ab-
sorption spectrum. In skin, DNA and urocanic acid have been identifi ed 
as such chromophores (Young et al., 1998; Hanson and Simon, 1998). 
Other endogenous choromophores include e.g., melanin, haemoglobins, 
porphyrins and tryptophan. Very recently, metabolic products of certain 
immunosuppressive drugs such as azatiophrine have been identifi ed also 
to act as a chromophore (O’Donovan, 2005). DNA has an absorption peak 
around 260 nm in the UVC-region but most of it is absorbed in the UVB 
region (290–320 nm) and also some in the UVA region (Figure 2). Th e 
absorption of photons by DNA opens the double bond of pyrimidines. 
When this takes place in two adjacent pyrimidines, so-called fi ngerprint 
mutations occur in DNA (e.g. C-> T, CC -> TT). Th ese mutations are con-
stantly being repaired by nucleotide excision repair (NER) (Gougassian et 
al., 2000). Th is system repairs the damaged base by excision repair, which 
is followed by DNA repair synthesis and ligation. When this repair fails, 
the abovementioned mutations characteristic for UV photodamage re-
main permanent. 
UV radiation and cutaneous carcinogenesis
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Mechanisms involved in carcinogenesis
Photocarcinogenesis is a multistep process involving initiation, promo-
tion, progression and fi nally metastasis. UVB irradiation is shown to be a 
complete carcinogen (Black et al., 1997). In squamous cell carcinoma UVB 
initiates as well as promotes cancer and has an eff ect on the progression of 
cancer (Pinnell, 2003). Th e action spectrum of UV irradiation for the gen-
eration of squamous cell carcinoma occurs mainly in the UVB spectrum, 
but there is also activity in the UVA spectrum (320–400 nm): in albino 
mice model the peak was in UVA radiation (de Gruijl et al., 1993). Th e ac-
tion spectrum of DNA damage, erythema and the generation of SCC are 
shown in Figure 2. In the fi sh model, the action spectrum for melanoma 
has been estimated to peak in the UVA region around 365 nm (Setlow et 
al., 1993). However, only UVB initiated melanoma in the mouse model 
(De Fabo et al., 2004). UVA radiation has been found to also induce signa-
ture mutations, like those in p53 gene, in human skin (Young et al., 1998; 
Agar et al., 2004), and UVA radiation is proposed to be important in tumor 
Figure 2 (adapted from the National Agency for Medicines)
Th e absorption spectrum of DNA damage, erythema and squamous cell carcinoma 
(SCC)
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promotion (de Gruijl, 2000). In cell cultures, the longer UVA wavelengths 
(340–400 nm) have been shown to induce apoptosis (Godar, 1999).
p53 is a protein whose major physiological role is to suppress the de-
velopment of cancer. It regulates a number of genes which lead to cell cy-
cle regulation and apoptosis (Lane, 1992). UVB fi ngerprint mutations can 
occur in p53 and they are believed to play a major role in the initiation 
of nonmelanoma skin cancer (Ziegler et al. 1993; Daya- Grosjean et al, 
1995).
Initially, failure in repairing photoproducts results in a mutation in ke-
ratinocytes. If this occurs in one allele of the p53 gene, the cells fail to un-
dergo apoptosis. If UV related photodamage in the genome is great enough 
to inactivate the remaining functional allele of p53, this can result in clonal 
expansion of keratinocytes and squamous cell carcinoma (Lane, 1992; Har-
ris, 1993; Steele and Lane, 2005). Squamous cell carcinoma is thus believed 
to develop step by step as a result of cumulative excessive lifetime exposure 
to UV radiation (Kricker et al., 1994). Convincing evidence of the impor-
tance of UV radiation in causing DNA damage is given by the studies of 
xeroderma pigmentosum patients (Cleaver, 1968). In these patients there 
is a defect in repair of UV radiation induced pyrimidine dimers and the 
risk of developing cutanous malignancies is approximated to be 2000 times 
higher compared to the general population (Yarosh et al., 2001).
Reactive oxygen species (ROS) are composed of free radicals and reac-
tive oxygen molecules (Pinnell, 2003). Th ey are formed in the mitocondrial 
electron chain by the cyclo-oxygenase pathway and by some other cellular 
enzymes (Ames et al., 1993). Increased oxidative stress and environmental 
factors, like UV radiation, can cause DNA damage through formation of 
ROS (Cadet et al., 1997). It has been speculated that the cutaneous UVA 
eff ects are mainly from indirect damage by ROS (de Gruijl et al., 1994), 
but both UVB and UVA radiation are capable of eliciting such a premuta-
genic oxidative DNA base damage (Kvam and Tyrrel, 1997). However, it 
seems that UVA must always react with a chromophore (e.g. melanin or 
porphorin) to generate ROS (Wang et al, 2001). 
UV radiation and immunosuppression
UV radiation is proven to be immunosuppressive in laboratory animals 
(Kripke, 1974). UV induced tumors were rejected upon inoculation in 
nonradiated syngeneic mice. Skin tumors induced by chronic treatment 
with UV light grew only when transferred to immunocompromized or 
UV irradiated mice (Kripke, 1974). In further investigations, it was no-
ticed that UV radiation induced immunosuppression can be divided to 
local and systemic immunosuppression. Th ese models have been studied 
in mice with low-dose and high-dose UV exposure settings (Beissert and 
Schwarz, 1999).
Local immunosuppression is induced with low dose UV irradiation. UV 
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exposure decreases the number of LCs in the skin. Th is leads to inability 
to sensitize mice to contact allergens. Later resensitization with the same 
allergen through unirradiated skin may again fail to reduce contact hyper-
sensitivity. Th is tolerance is mediated through antigen specifi c T cells. In 
local immunosuppression, contact hypersensitivity reactions were not af-
fected on nonirradiated skin (Beissert and Schwarz, 1999). 
UV radiation localized to a limited skin area has been shown to inhibit 
the induction of the immune response in a distant skin area not exposed 
to UV radiation (Noonan et al., 1981). Th is phenomenon is called sys-
temic immunosuppression. Also, this systemic immunosuppressive eff ect 
is transferred in T lymphocytes from one animal to another (Fisher and 
Kripke, 1982). Various cytokines released by UV exposed keratinocytes 
take part into this process. Th e most important seems to be IL-10 (Rivas 
and Ullrich, 1992) and others include TNF-alfa and TGF-beta (Schwartz 
et al., 1986). Th e strong induction of IL-10 by UV radiation suggests that 
UV exposure is capable of shift ing cellular immune system responses to-
wards a Th 2- type reaction (Ullrich, 1995). Th 1 cells help tumor rejection 
and suppression of the Th 1 arm can enhance the carcinogenic properties 
of UV radiation. 
LCs have the major antigen presenting role in the skin and they also 
present malignant neoantigens. UVB radiation decreases the number of 
these LCs in a dose-dependent manner (Koulu et al., 1985), and alters also 
their morphology by destroying the dendrites. UV radiation suppresses 
the expression of MCH class II surface molecules (Aberer et al., 1981). 
Aft er high dose UV irradiation, the reduced number of LC’s seems to be 
replaced by LC precursors from the blood (Merad et al., 2002). In animal 
models, UVA has also caused a signifi cant reduction in the number of epi-
dermal APCs (Bestak and Halliday, 1996). Th e reduction of LCs induced 
by PUVA is known to return back to normal within three weeks aft er stop-
ping of PUVA treatment (Friedman et al., 1983). Th us, it is not surprising 
that PUVA therapy (topical or oral) can down-regulate hypersensitivity 
responses (Kripke et al., 1983; Aubin et al., 1991).
Urocanic acid is suggested to be the photoreceptor for UV induced im-
munosuppression besides DNA. Urocanic acid is postulated to have pho-
toprotective mechanisms such as to protect the skin agains sunburn and to 
protect DNA in epidermal keratinocytes from actinic damage (Zenisek et 
al., 1955; Morrison, 1985). Irradiation with UVB isomerizes trans-urocanic 
acid to cis-urocanic acid. Cis-urocanic acid is known to suppress cell- me-
diated immunity (Aubin, 2003). To support the immunosuppressive eff ects 
of cis-urocanic acid, cis-urocanic acid injected into the skin destroys LCs.
Immunosuppressive treatments have a clear eff ect on cutaneous cars-
inogenesis. Th e risk of skin cancer is increased in patients treated with 
immunosuppressive agents. Th is is well documented in organ transplant 
patients. Th e role of ultraviolet radiation in the pathogenesis of skin can-
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cers is important in this patient group. Skin tumors are typically located on 
sun-exposed areas like the lip, hands and scalp. Th e degree of sun exposure 
is highlighted in studies made in diff erent countries: the frequency of skin 
cancer aft er organ transplantation is higher in Australia than in the Neth-
erlands (Hartevelt et al., 1990; Sheil, 1992). 
Skin cancer
Human skin cancers can be divided into two types based on the origin of 
the malignant cell: nonmelanoma skin cancer and malignant melanoma. 
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) originate 
from keratinocytes. 
Basal cell carcinoma
Basal cell carcinoma (BCC) is the most common skin malignancy arising 
from undiff erentiated basal cells normally capable of diff erentiation into 
structures such as sweat glands and hair (Miller, 1991). Histologically they 
are composed of uniform cells with darkly stained nuclei and they oft en 
form typical palisading structures (McKee, 2005). Basal cell carcinomas 
are most common on sun- exposed areas like the face, scalp, forehead and 
cheeks. Th ere are three diff erent subtypes of basal cell carcinoma: nodular, 
superfi cial and morpheaform (or sclerosing) basal cell carcinoma. Usually, 
basal cell carcinoma presents as an ulcerated or crusted centre with a dis-
tinct raised edge with a pearly appearance. Morpheaform basal cell carci-
noma makes a challenge in clinical diagnosis.
Basal cells (keratinocytes) are more tolerant to UV radiation than sq-
uamous cells because of their stem cell type properties (Miller, 1991). It 
is believed that not only cumulative exposure to UV radiation but also 
intensive skin burning is a major risk factor for the development of basal 
cell carcinoma (Kricker et al., 1995).
Squamous cell carcinoma
Squamous cell carcinoma arises from diff erentiated epidermal keratinoc-
ytes and it develops step by step from its precursors actinic keratosis and 
Morbus Bowen (carcinoma in situ). In actinic keratosis (AK) the cells show 
abnormal epidermal growth and disordered keratinisation. AK may be re-
versible. 
Nuclear atypia is seen in Morbus Bowen, but the changes are above the 
basement membrane zone. Squamous cell carcinoma arises at the point 
when atypical keratinocytes invade the dermis. Th e favourite sites for SCC 
are the dorsal aspects of the hands and forearms. Th e clinical appearance is 
usually a crusted scaly ulcer or more nodular tumour. 
Epidemiological evidence of the role of UV radiation in the develop-
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ment of squamous cell carcinoma is strong. Th e incidence of SCC is in-
creased in sunny climates and is related to the skin type. In an Australian 
study the risk factors for SCC and BCC were compared in a case-control-
led study. Th e risk of both cancers was found to be higher in persons born 
in Australia than in immigrants with Caucacian ancestors (Kricker et al., 
1991). Fair skin type, as well as indicators of previous sun damage (e.g., 
actinic keratosis, facial teleangiectasia, solar elastosis), were risk factors of 
SCC and BCC. Th e incidence of SCC and BCC increases with the age. In a 
Welsh study, the incidence of SCC among patients aged over 75 years was 
35 times higher than that of patients between 50 and 55 years and the fi gure 
for BCC was fi ve times higher, respectively (Holme et al., 2000). Th us, the 
incidence of SCC rises more rapidly than that of BCC. However, in Finland 
the incidence of BCC has risen more rapidly (Cancer in Finland, 2003). 
Comparison between diff erent types of skin cancer in diff erent countries 
is diffi  cult to make due to lack of proper registries. Th e incidence fi gures of 
SCC are comparable only in Scandinavian countries.
Malignant melanoma
Malignant melanoma (MM) is more uncommon than SCC and BCC, 
but its incidence has risen (Hall et al., 1999). Melanoma is divided into 
four subtypes: nodular, superfi cial spreading, lentigo maligna and acral 
melanoma. Clinically melanomas are dark pigmented, irregularly shaped 
asymmetrical lesions with colours of black, blue, red, white or brown. 
Compared to BCC and SCC, melanoma has a diff erent age-distribution. 
One half of melanomas are found in patients under 55 years of age and one 
third occurs before the age of 45 (Diepgen and Mahler, 2002).
Cutaneous malignant melanoma arises from epidermal melanocytes. 
Th ere is variable information, but 17–51% of melanomas arise from pre-
existing nevus cells (Skender- Kalnenas et al., 1995). Some families have an 
increased incidence of melanoma. Most of these patients have dysplastic 
nevus syndrome. Previous studies have located the gene of this syndrome 
to chromosome 1 (Bale et al., 1989). In Dutch studies , these patients have 
been shown to share the same deletion of the p16 gene (van der Velden 
et al., 2001). In one study patients with 50–100 nevi had a 3.2-fold in-
creased risk and patients over 100 nevi 7.7 times risk for the development 
of melanoma compared to persons with 0–4 nevi (Bataille et al., 1996). 
Th e same study found that patients with four or more atypical nevi had a 
relative risk for the development of melanoma of 14.3. Other background 
risk factors related to melanoma are a history of previous melanoma, a 
positive family history of melanoma and giant congenital pigmented hairy 
nevus (Roberts et al., 2002). Exposure to UV radiation is accepted to be a 
major etiological factor, but the role of UV light is complex. In the etiology 
of melanoma the degree of sunburn seems to be more important than sun 
exposure per se, since melanoma is thought to be associated with intense 
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intermitted sun exposure (Holdman et al., 1986; Gallagher et al., 1990). 
Although some studies claim that the risk is especially increased with a 
history of fi ve or more sunburn events (Weinstock, 1996), the explanatory 
mechanism is unclear. 
Unlike SCC, most melanomas occur in light-skinned people on parts of 
the body exposed to the sun intermittently, such as legs in women (47% of all 
melanoma cases in women) and trunk of men (36% of all melanoma cases 
in men). Some studies have also shown an increased risk of melanoma in 
indoor workers compared to outdoor workers (Beral and Robinson, 1981; 
Vagero et al., 1986). Melanoma risk also increases in fair-skinned people 
with blond or red hair and a tendency to get freckles easily. Th e melanocor-
tin 1 receptor (MC1R) is essential in the regulation of variation in normal 
human pigmentation. MC1R is expressed on melanocytes and melanoma 
cells. A strong relationship between melanoma risk and the MC1R geno-
type variants has been shown (Healy et al., 2000; Palmer et al., 2000). One 
variant of this MC1R genotype appeared to be able to cause fair skin and 
increased melanoma risk (Healy et al., 2000). Th e exact mechanism how 
the risk of melanoma is increased is not known. It has been shown that 
the same MC1R gene variants have also been linked with an increased risk 
of SCC and BCC (Palmer et al., 2000; Bastiaens et al., 2001). Th e world´s 
highest melanoma risk in detected in Australia, which may be explained by 
the latitude of the country and large population of Celtic-origin (Mack and 
Floderus, 1991; MacLennan et al., 1992). Th e exact spectrum of radiation 
responsible for melanoma is not known. 
In melanoma, the p53 mutations are less prominent (1–9%) than in 
nonmelanoma skin cancers (41%) (Hartman et al., 1996; Steele and Lane, 
2005). Also in melanoma, the observed p53 mutations are found at dipy-
rimide sites. In melanoma metastases these mutations are more frequent 
in skin metastases than those of internal organs (Zerp et al., 1999) showing 
evidence of UV radiation induced mutagenesis of p53.
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Photochemotherapy
Th e diff erent wavelengths of various phototherapy treatments are shown 
on Figure 3.
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Figure 3 (adapted from the National Agency for Medicines)
Th e spectral distribution of diff erent phototherapy light sources
(nb-UVB=narrowband UVB)
PUVA
Psoralen photochemotherapy (PUVA) is a combination of the drug pso-
ralen and UVA radiation. Psoralens are furocoumarins originally derived 
from plants. In clinical practice, the most oft en used are 8-methoxypso-
ralen (8-MOP) and trimethylpsoralen (TMP) (Figure 4). Psoralens are 
biologically reactive only if activated with UVA radiation. First, psoralens 
intercalate in the DNA double strand between adjacent base pairs, then 
aft er UVA irradiation psoralens form pyrimidine-psoralen monoadducts 
and fi nally, aft er more irradiation a pyrimidine-psoralen-pyrimidine com-
plex in the DNA duplex is formed. Th e fi nal result is a covalent interstrand 
psoralen-DNA crosslink, which inhibits DNA replication and causes the 
cell cycle arrest (Lauharanta, 1997).
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Psoralens can be administered orally or topically. Oral administration 
has systemic eff ects such as nausea and ocular side-eff ects. Th erefore, oral 
PUVA treatment is also called systemic PUVA treatment. Psoralen used in 
this regimen is 8-MOP. Bath PUVA was developed in the 1970s because it 
lacks the disadvantages of systemic PUVA. Trioxalen bath +UVA was in-
troduced in Sweden (Fischer and Alsins, 1976). TMP and 8-MOP are both 
used in bath PUVA. Depending on the route, psoralens are administrated 
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Figure 4
Common psoralens in clinical use
8-methoxypsoralen
trimethylpsoralen
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15 minutes to 2 hours before the irradiation. For psoriasis, the routine oral 
administration is 0.4–0.8 mg/kg of 8-MOP. PUVA therapy should be given 
at least 72 hours apart to avoid cumulative delayed cutaneous phototoxic-
ity. Some of the most common indications for PUVA treatment are listed 
in Table 1. 
Table 1
Indications for PUVA therapy
(Atopic dermatitis)
Chronic hand dermatitis
Graft -versus-host-disease
Granuloma annulare
Lichen planus
Lymphomatoid papulosis
Mycosis fungoides
Palmoplantar pustulosis
Prurigo nodularis
Psoriasis
Urticaria pigmentosa
Th e capability of PUVA to induce apoptosis in lymphocytes is utilized 
in CTCL and lymphocyte associated skin diseases (Johnson et al., 1996). 
PUVA has also been shown to have an eff ect on various cytokines and cy-
tokine secretion, which in turn normalizes the excelerated keratinocyte 
turnover rate in psoriasis (Averbeck, 1989).
Carcinogenic effects of systemic PUVA therapy
Since the beginning of the use of systemic PUVA therapy there has been 
concern of the carcinogenic risk of this treatment. 8- methoxypsoralen + 
UVA is mutagenic in bacteria (Kirkland et al., 1983). PUVA therapy has 
numerous immunosuppressive eff ects both in vitro and in vivo: it reduces 
the number of APCs (Friedmann, 1981; Ree, 1982), the amount of mast 
cells (Toyota et al., 1990), and the number of helper T cells in psorisis pa-
tients (Moscicki et al., 1982). It also depresses natural killer cell activity 
and suppresses delayed hypersensitivity reactions (Vella Briff a et al., 1981; 
Viander et al., 1984). 
PUVA therapy and UVB generate diff erent types of DNA damage re-
sulting in specifi c types of p53 mutations (Nataraj et al., 1996). Th ese mu-
tations have been looked for in squamous cell carcinoma of PUVA treated 
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psoriasis patients. Nataraj et al. found that a signifi cant number (64%) of 
p53 mutations were of the C-T or CC-TT types, which are usually related 
to UVB irradiation, whereas PUVA type mutations are usually T-A (Na-
taraj AJ et al., 1997). Frequent UVB signature C->T transitions were also 
found in the p53 tumor suppressor gene (Peritz and Gasparro, 1999). Stern 
et al., found 46% of p53 mutations in PUVA treated patients to be of only 
UVB type, 5% of only PUVA type and rest (49%) of both types (Stern et al., 
2002). However, in tumors in patients with high-dose exposure to PUVA, 
UVB type mutations were less frequent than the PUVA type. One mecha-
nism, by which PUVA treatment can induce fi ngerprint mutations in py-
rimidine bases, is through generation of the ROS (Reid and Loeb, 1993; 
Filipe et al., 1997).
Systemic PUVA was introduced for the treatment of psoriasis in the 
mid 1970´s (Parrish et al., 1974). Almost all epidemiological data about 
the carcinogenic risk of systemic PUVA is obtained from psoriasis pa-
tients. Th e fi rst report of increased SCC risk was an American PUVA fol-
low up study in 1979 (Stern et al., 1979). In this study, an increased risk 
of nonmelanoma skin cancer was found only in association with a previ-
ous history of NMSC, ionizing radiation and fair skin (type I or II). Th e 
subsequent reports from this study have demonstrated a dose-dependent 
relationship between systemic PUVA exposure and SCC unassociated with 
other risk factors (Stern et al., 1984; Stern et al., 1988; Stern and Laird, 
1994). Since then, many prospective or retrospective cohort studies have 
been performed. In the 1980’s most non-American studies found no in-
creased risk in skin cancer (Lindskov, 1983; Cox et al., 1987;), and in some 
studies skin cancers were associated with systemic PUVA treatment only 
with previous exposure to other possible carcinogenic treatments such as 
arsenic, UVB and methotrexate (Maier et al., 1986; Henseler et al., 1987). 
Clear co-carcinogenic risk factors for skin cancer are ionizing radiation, 
previous skin cancer and previous arsenic treatment (Höningmann et al., 
1980; Reshad et al., 1984; Stern et al., 1984; Stern et al, 1988). 
One large Swedish study of 4799 patients treated with PUVA showed a 
dose-dependent increase in the risk of SCC. Th ese patients were followed-
up for an average of 7 years. Th e majority of these patients (77%) had re-
ceived oral 8-MOP. Male patients who had received more than 200 PUVA 
treatments had over 30 times the risk of SCC compared to the general 
population (Lindelöf et al., 1991). In a study of Dutch psoriasis patients 
treated with systemic PUVA, the incidence of squamous cell carcinoma 
was increased. Th e average follow up time was 8.6 years, and a 12-fold risk 
compared to general population was found (Bruynzeel et al., 1991). Th is 
study used a quite aggressive treatment schedule resembling more the in 
American studies. Th e average total dose was 824 J/cm2 and all squamous 
cell carcinomas occurred at doses more than 1000 J.
Systemic PUVA treatment induces pigmented macular lesions, called 
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PUVA lentigines (Rhodes et al., 1983b). Th ese lesions are histologically 
composed of large, sometimes atypical melanocytes (Rhodes et al., 1983a). 
Th is fi nding had aroused concern about a possible melanoma risk related 
to PUVA therapy. Until the year 1997, there were some case reports of 
melanomas appearing during PUVA therapy. In these individuals, the 
number of preceding PUVA treatments varied from 40 to 194 (Kemmet et 
al., 1984; Gupta et al., 1988; Bergner and Przybilla, 1992). In 1998 Wolf et 
al., reported three melanoma cases in PUVA treated patients. Th e number 
of exposures varied between 31 to 501 and none of them had received UVB, 
methotrexate or x-ray treatment previously (Wolf et al., 1998).
Th e carcinogenic risk of bath PUVA has been studied extensively in 
Scandinavia. Trioxalen bath PUVA did not increase the risk of SCC in pso-
riasis patients (Hannuksela et al., 1996; Hannuksela-Svahn et al., 1999b). 
Th e overall cancer risk did not increase in psoriasis patients treated with 
8-MOP bath+UVA. In this study, the risk of SCC was not increased (Han-
nuksela-Svahn et al., 1999a).
Also, in mycosis fungoides patients who had repeatedly received PUVA 
therapy, a couple of malignant melanoma cases were reported. Reseghetti 
et al. reported of a patient with a history of 134 times of PUVA treatment 
(Reseghetti et al., 1994). Th e diagnosis of melanoma was made 7 months 
aft er the start of the therapy. Although the follow-up time in this case was 
short, both mycosis fungoides (lymphoma) and PUVA therapy could have 
lowered the patient´s immunity but the authors speculate the fi nding be 
due to a change. In a series of 164 CTCL patients, all treated with total skin 
electron beam therapy, six developed melanoma and three of them had re-
ceived additional PUVA therapy (Licata et al., 1995).Twenty-four patients 
developed 34 squamous cell carcinomas and over 37 basal cell carcinomas. 
In these patients, PUVA therapy was signifi cantly associated with the de-
velopment of both squamous cell carcinoma and basal cell carcinoma, but 
not to melanoma. 
Other phototherapy regimens 
Broad-band UVB, narrow-band UVB 
Th e spectrum of broad-band UVB light sources is seen in Figure 3. Th e 
maximal therapeutic eff ect for psoriasis is between 310–315 nm, whilst 
the maximum eff ect of burning is achieved at 290–300 nm (Young, 1995). 
Narrow-band UVB (311 nm emission) was introduced in the late 1980s as 
an alternative for conventional UVB therapy and PUVA therapy in clinical 
practice. It was found to be superior to broadband phototherapy in atopic 
dermatitis and psoriasis (van Weelden et al., 1988; Grundmann-Kollman 
et al., 1999). Th e indications for UVB phototherapy (narrow- and broad-
band) are shown in Table 2. Narrow-band UVB treatment is as effi  cient as 
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systemic PUVA in the treatment of psoriasis (Dawe et al., 2003; Snellman 
et al., 2004).
Table 2
Indications to broadband and narrow-band UVB
Atopic dermatitis
Generalized dermatitis
Lichen planus
Parapsoriasis
Prurigo nodularis
Pruritus
Psoriasis
SUP
In Finland, sources emitting UVA and UVB light are called SUP devices. 
Th e spectrum of SUP is seen in Figure 3. In other European countries the 
equivalent for SUP is helarine photon therapy. Th e emission spectrum of 
SUP devices resembles the spectrum of the sun. Th ere are no reports of the 
SUP-treatment carcinogenity. Th e most common indications of SUP are 
presented in Table 3.
Table 3
 Indications for SUP
Atopic dermatitis
Generalized eczema
Lichen planus
Pruritus
Psoriasis (children)
Cyclosporine
Cyclosporine is a cyclic endecapeptide of 11 amino acid residues, which 
was originally isolated from a soil fungus (Tolypocladium infl atum Gams). 
Th e immunomodulatory property of cyclosporine was introduced in 1976 
(Borel et al., 1994). Th e drug was fi rst used in organ transplant patients (du 
Toit et al., 1985). Also, it has been widely used in various skin diseases e.g. 
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in psoriasis, diff erent eczemas including atopic dermatitis and pustulosis 
palmoplantaris (Mueller and Herrmann, 1979, Ellis et al., 1991, Reitamo 
et al., 1993). 
Within the cell, cyclosporine forms a complex with cyclophilin, which 
binds to and inhibits the activity of the intracellular enzyme calcineurin 
phosphatase. Th e inactivation of calcineurin inhibits the nuclear transloca-
tion of transcription factors for the transcription of interleukins (Krönke et 
al., 1984), the most important of which is IL-2. IL- 2 is the main activation 
factor for T cells. Cyclosporine has also an inhibitory eff ect on histamine 
release from mast cells resulting in anti-infl ammatory eff ects (Narita et al., 
1998). Cyclosporine targets T cell proliferation and activation and these 
properties are utilized in various infl ammatory skin diseases where the 
role of T cells is crucial.
Cyclosporine is administered orally and the recommended maximum 
dosage in skin diseases is 5mg/kg. Th e median half-life is 6.4–8.6 hours, 
which gives the possibility of twice a day administration (Ptachcinski et al., 
1986). Nephrotoxicity, increased blood pressure and immunosuppression-
induced malignancies are the main side eff ects of cyclosporine. Th e renal 
changes are clearly dose dependent (Ellis et al., 1991) but the mechanisms 
for cyclosporine-induced hypertension is not understood. In long-term 
treatment almost half of the patients can develop hypertension (Fry et al., 
1988). Also, cyclosporine induced hypertension is dose-related.
Cyclosporine and cancer
Basically all drugs that eff ect the immune system carry a possible risk of 
increased cancer. In the case of cyclosporine, this can be explained by two 
diff erent mechanisms. In in vitro models, cyclosporine has been shown to 
have direct carcinogenic activity (Hojo et al., 1999). Cyclosporine induced 
non-invasive adenocarcinoma cells invasive, which was speculated to be 
a result of TGF-beta infl uence. Th ese cancer cells also developed invasive 
characteristics. On the other hand, in animal models chronic immunosup-
pression resulting from medication like cyclosporine is thought to inter-
act with the expression of antigen-induced signals that are needed for the 
generation of T cell dependent immune responses (Servilla et al., 1987). In 
mice, cyclosporine shortens the time needed for tumor induction by UV 
irradiation (Kelly et al., 1987). One recent in vitro study compared the ef-
fects of four immunosuppressive drugs on the growth of various tumor cell 
lines (Casadio et al., 2005). Th ey found that all other immunosuppressive 
agents, except cyclosporine, inhibited the growth of these cell lines.
In organ transplant patients, immunosuppressive therapy is always com-
bination therapy. Th erefore the role of individual drugs is diffi  cult to judge, 
and the carcinogenic eff ect of cyclosporine is largely based on data from 
organ transplant patients. Th e role of cyclosporine is controversial. Some 
studies have shown that cyclosporine-based immunosuppression increases 
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the risk of squamous cell carcinoma more than combination treatments 
(azathioprine and prednisone) (Glover et al., 1997; Marcen et al., 2003). In 
another study, patients with cyclosporine and prednisone showed a higher 
risk of squamous cell carcinoma than patients with azathioprine and pred-
nisolone, but a lower risk when compared to patients taking all three drugs 
simultaneously (Jensen et al., 1999). One study showed a dose-related link 
between cancers and cyclosporine. In this study in renal transplant recipi-
ents the frequency of skin cancer was signifi cantly higher in a high-dose 
regimen than in a low-dose regimen. Th e same eff ect was detected with 
noncutaneous cancers, but the diff erence was not signifi cant (Dantal et al., 
1998). In organ transplant patients, the most common skin cancers are 
squamous cell carcinoma and basal cell carcinoma, which cover over 90 
per cent of all skin cancers in this group (Bouwes-Bavink et al., 1996; Webb 
et al., 1997; Jensen et al., 1999). Th e other cancers include lymphomas, 
Kaposi’s sarcoma and cancer of the anogenital region (Stockfl eth et al., 
2001; Euvrard et al., 2003). In organ transplant patients, the risk of cancer 
is dose-dependent being highest in multiorgan and heart transplant pa-
tients (Euvrard et al., 2003). Th e risk of getting nonmelanoma skin cancers 
increases rapidly with time, and aft er 20 years of transplantation, almost 
half of Caucasian patients in most western countries and 70–80 per cent 
of Caucasian Australian patients develop at least one nonmelanoma skin 
cancer (Webb et al., 1997; Jensen et al., 1999; Ramsay et al, 2002).
Th e carcinogenic risk of cyclosporine in other patients than organ 
transplant patients has been quite sparsely reported until recently. In a US 
study with psoriasis patients, cyclosporine use was found to be a risk fac-
tor for the development of squamous cell carcinoma. In this nested cohort 
crossover study, any use of cyclosporine increased the risk of squamous 
cell carcinoma as much as 200 PUVA treatments (Marcil and Stern, 2001). 
In another cohort study, the use of cyclosporine was associated with a 6-
fold higher incidence of skin malignancies (Paul et al., 2003). When one 
hundred atopic patients were treated with cyclosporine for 48 weeks, only 
one basal cell carcinoma was detected (Berth-Jones et al., 1997). Cohort 
studies without risk analyses have reported two lymphoma cases in pso-
riasis patients receiving cyclosporine (Krupp and Monka, 1990), but in 
another study no lymphoma cases were found (Christophers et al., 1992). 
In addition, some anecdotal reports of lymphomas occurring shortly aft er 
discontinuation of cyclosporine treatment have been reported (Koo et al., 
1992; Zijlmans et al., 1992; Masouye et al., 1993). Lymphomas have also 
been detected during cyclosporine treatment in psoriasis patients and au-
toimmune patients (Cockburn et al., 1989; Cliff  et al., 1999).
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Methotrexate
Methotrexate is a folic acid antagonist, which was fi rst introduced in the 
fi eld of dermatology in the late 1950s (Edmundson and Guy, 1958). Its 
most important mode of action is the inhibition of dihydrofolate reduct-
ase enzyme, which blocks the synthesis of thymidine monophosphate. Th is 
further results in the inhibition of DNA and RNA synthesis. Methotrexate 
thus has an antiproliferative eff ect. Th e most feared side eff ects are bone 
marrow toxicity including pancytopenia, toxicity to gut and to mucous 
membranes. Others include alopecia, hepatic toxicity, renal failure, pneu-
monitis and osteoporosis (Souhami and Tobias, 2005). In dermatology, 
methotrexate is used once a week administration and the dosage is usu-
ally 7.5–15 mg but can be elevated up to 30 mg per week. Th e indications 
for use of methotrexate are e.g. psoriasis, mycosis fungoides, sarcoidosis, 
atopic dermatitis, pityriasis rubra pilaris, pityriasis lichenoides, dermato-
myositis and SLE (Braun-Falco, 2000; Dadlani and Orlow, 2005).
Methotrexate and cancer
Th ere are no reports on the carcinogenity of methotrexate itself. In pa-
tients with rheumatoid arthritis, methotrexate combined with TNF-al-
pha inhibitor treatment, the hazard ratio of nonmelanoma skin cancer 
was 1.97, whereas methotrexate treatment alone did not increase the risk 
(Chakravarty et al., 2005). In a small American cohort (134 patients), the 
transformation of mycosis fungoides to large cell lymphoma was studied. 
In patients treated with methotrexate, the incidence of transformation was 
signifi cantly higher (14.3%) than in patients not treated with methotrexate 
(1.8%) (Abd-el-Baki et al., 2002). Both these studies suggest that methotrex-
ate may act as a promoter in carcinogenesis. In psoriasis patients, expo-
sure to methotrexate signifi cantly increased the risk of nonmelanoma skin 
cancer (RR 2.7; 95% CI=1.1–7.3), but the eff ect of methotrexate was not 
separately analyzed (Paul et al., 2003). In the PUVA follow up study, high 
level exposure to methotrexate versus no exposure increased independ-
ently the risk of squamous cell carcinoma (RR 2.1; 95% CI=1.4–2.8) (Stern 
and Laird, 1994). Similar results were found by Lindelöf and Sigurgeirs-
son, where in psoriasis patients treated with PUVA, previous methotrexate 
therapy increased the risk of squamous cell carcinoma (RR 3.5, 95% CI= 
1,2–9.9) (Lindelöf and Sigurgeirsson, 1993). In a Finnish case controlled 
study in psoriasis patients, methotrexate was not found to increase the risk 
of squamous cell carcinoma (Hannuksela-Svahn et al., 2000)
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Aims of the study
Th e main purpose of the present study was to investigate the cancer risk 
related to two immunosuppressive treatments, systemic PUVA treatment 
and cyclosporine, widely used in infl ammatory skin diseases. Th e specifi c 
aims were:
1.  to investigate the possible association between systemic PUVA treat-
ment and melanoma
2.  to investigate the possible association between systemic PUVA treat-
ment and noncutaneous cancer
3.  to assess the persistence of skin cancer risk among patients treated with 
systemic PUVA, including also patients without substantial exposure to 
other carcinogens or patients who have discontinued PUVA treatment
4.  to assess the risk of secondary cancer in cutaneous T cell lymphoma 
patients and to investigate their association with previous photoche-
motherapy 
5.  to investigate the risk of cancer related to short term cyclosporine treat-
ment in patients with severe chronic infl ammatory skin diseases 
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Patients and methods
Patients and data collection
Psoriasis patients
Studies I–III are based on a prospective follow-up study conducted in six-
teen university centers in the USA. Th ese original centers include Stanford 
University School of Medicine, University of California Medical School, 
Baylor College of Medicine, Washington Hospital Center, University of 
Michigan Medical School, Columbia University College of Physicians and 
Surgeons, Mayo Graduate School of Medicine, Mt Sinai Medical Center, 
Temple University School of Medicine, Beth Israel Hospital, Dartmouth 
Medical School, Yale University School of Medicine, Duke University 
Medical Center, University of Pennsylvania Hospitals, Massachusetts Gen-
eral Hospital and Harvard Medical School (the cordinating center). During 
the period from January 1, 1975, through October 1, 1976 altogether 1380 
psoriasis patients were enrolled to this study. Th e study closed at the end 
of June, 2005. At this time, there were 526 patients in the study. Th e initial 
aim of the study was to assess the long-term risks and benefi ts of PUVA 
therapy. On average, every 15 months aft er enrolment, all study patients 
had interviews and dermatologic examinations regardless of whether or 
not they continued to use PUVA. Each patient´s exposure to alternative 
carsinogens (UVB radiation, tar, methotrexate and ionizing radiation) used 
for their psoriasis treatment were documented before and aft er initiation 
of PUVA treatment. Th e patients had received a standard PUVA protocol 
consisting of 0.4–0.6 mg/kg oral psoralen and followed 1.5–2 hours later 
by UVA treatment. Th e starting dose of UVA was dependent of each pa-
tients photosensitivity. Typically, patients reached a maximum UVA dose 
of 8–15 J/cm2. Th e treatment was slowly tapered off  when their psoriasis 
cleared. Th e diagnosis of cutaneous tumors were verifi ed by a pathologist 
or dermatologist. 
Cutaneous T cell lymphoma patients
Study IV was a retrospective study consisting of 319 patients with a histo-
logically confi rmed diagnosis of CTCL. Th e patients were collected from 
the Finnish Cancer Registry between the years 1953 and 1995. For all sub-
sequent 12 lung cancer cases detected among these CTCL patients, the pa-
tient charts were examined to fi nd out their previous treatments. 
Patients and methods
37
Skin disease patients
For study V, we analyzed a cohort of 272 patients with a diagnosis of pso-
riasis, atopic dermatitis, palmoplantar pustulosis or chronic hand eczema 
during years 1987–1998. All patients were from the Skin and Allergy Hos-
pital, Helsinki. Th e patients had received at least one month of cyclosporine 
therapy. Th e initial criteria for the use of cyclosporine therapy were as 
follows: in psoriasis and atopic dermatitis moderate or severe disease, in 
palmoplantar pustulosis at least 20 fresh pustules in palms or soles and 
in chronic hand eczema therapy resistant disease (Rajka and Langeland, 
1983; Reitamo et al., 1993; Granlund et al., 1995; Granlund et al., 1996). 
From these patients, information regarding cyclosporine duration, dosage 
of cyclosporine, phototherapy (PUVA, UVB, SUP), methotrexate and dos-
age of methotrexate was collected from the patient charts. 
Th e mean age and sex distribution of all patients in these studies are 
shown in Table 4.
Table 4 Age and sex distribution of the patients in each study
Study number (number of patients) Mean age (years) Sex distribution
I–III (1380)  44*  65% males
IV (319)  65**  57% males
V (272)  39  43% males
* at the time of enrollment, ** at the time of diagnosis (CTCL)
CTCL=cutaneous T cell lymphoma
Finnish Cancer Registry
Th e population-based nationwide Finnish Cancer Registry was established 
in 1952. It is supervised by the National Research and Development centre 
for Welfare and Health, and run by the Cancer Society of Finland. It is ob-
ligatory for all physicians, hospitals, health care centers, pathological and 
haematological laboratories to report all cancer cases that come to their 
attention. In addition, the information from all death certifi cates in which 
a cancer diagnosis is mentioned comes into the Finnish Cancer Registry. 
All cancers are registered according their primary site and ICD 1955 codes. 
Th e coverage is very high: nearly ninety-nine per cent of cancer cases are 
included (Teppo et al., 1994). 
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Statistical methods
Study I 
Th e designation of this study was based on the observation that aft er 15 
years of the fi rst PUVA treatment the incidence of melanoma started to 
increase or the patients had to have 280 PUVA treatments. Over 250 PUVA 
treatments were therefore determined as a high PUVA dose and under 250 
treatments as a low PUVA dose. Patients were categorised according to 
their cumulative PUVA exposures to previously mentioned groups. Th e 
number of melanomas were calculated based on published data from the 
Surveillance, Epidemiology, and End Results Program of the National 
Cancer Institute (SEER, 1995) in each of these four categories (>250 vs. 
<250 and >15vs. <15 years).
For statistical analyses we used a Poisson regression model and the results 
were presented as rate ratios and 95 per cent confi dence intervals (Gahlin-
ger and Abrahamson, 1993). We used this model to determine if the level 
of PUVA exposure and the time since the fi rst treatment had any eff ect on 
the risk of melanoma development (STATA reference manual, 1997). 
We used a Poisson regression model to factor sex, age and the increase in 
the incidence of melanoma into the calculations of the number of melano-
mas expected in each group. As independent predictors, we tested the 
number of PUVA treatments and time from the fi rst treatment.
Study II
Th e number of expected noncutaneous cancers was calculated on the basis 
of age-specifi c data obtained from the SEER. We used age- and sex-specifi c 
incidence rates for white people for each year during years 1975–1992. To 
calculate the expected number of tumors for 1993 to 1996, the incidence 
rates of 1992 were used. Th e incidence rate ratios were calculated on the 
basis of the number of observed and expected cancers and to calculate 95 
percent confi dence intervals we used the Poisson distribution.
Study III
Th e risk factors for the development of SCC or BCC were compared for 
two 10 year periods: before 1985 and aft er 1985. Th e cohort was divided 
into four categories according to the number of PUVA treatments before 
beginning of 1986: under 100, 100–159, 160–336, over 337. For multivari-
ate analysis, the exposure of diff erent potential cutaneous carcinogens were 
classifi ed as follows: UVB therapy (high dose >300 treatments), meth-
otrexate (high dose > 208 weeks), topical tar (high dose >45 months). For 
all the patients that had not developed SCC or BCC by the beginning of 
January fi rst, 1986, the expected number of tumors were calculated based 
on age-, sex-, and geographic area specifi c rates. For SCC and BCC, the 
head or neck were calculated separately. Th e expected SCC’s or BCC’s were 
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calculated in each PUVA category as described above. Th e relative risk of 
both cancers was compared to that expected on the basis of population 
incidence rates. Aft er that, site specifi c expected numbers were calculated 
assuming that in the general population 65% of squamous and basal cell 
carcinomas occurred on the head and neck and 35% developed on other 
skin sites (Giles et al., 1988; Gallagher et al., 1990; Magnus, 1991).
To analyse the association of various types of exposure and the risk of 
the development of SCC or BCC, we used Poisson regression model. Th e 
results were presented as rate ratios and 95 per cent confi dence intervals. 
All tests used were two sided.
Studies IV and V
Th e fi les obtained from Finnish Cancer Registry and based on personal 
identifi cation numbers, were linked to cohorts (studies IV, V) to obtain the 
follow-up for cancer. Th e follow-up period for subsequent cancers started 
from the fi rst month following the diagnosis of CTCL (IV) and from the 
date of starting cyclosporine treatment (V) and ended at the date of death, 
emigration, December 31, 1995 (IV) or December 31, 2003 (V), whichever 
came fi rst. Th e numbers of observed cancer cases and person years at risk 
were calculated for calendar periods by gender and fi ve-year age groups. 
To obtain the expected numbers of cancer, age-, sex-, and periodic-specifi c 
Finnish incidence rates were applied to the appropriate person-years under 
observation (studies IV, V).
Standardized incidence ratios (SIR) were defi ned as the ratio of ob-
served to expected numbers of cases. Assuming a Poisson distribution, we 
calculated 95 percent confi dence intervals (studies IV, V). Cox regression 
model was used to evaluate the infl uence of diff erent covariates to the de-
velopment of subsequent cancer (V). For statistical analyses, we used SPSS 
for Windows version 12.0 (study V).
Statistical methods
40
Results
Risk of malignant melanoma in psoriasis patients treated 
with systemic PUVA therapy (study I)
Th e risk of malignant melanoma in 1380 psoriasis patients treated with 
oral (8-MOP) PUVA therapy was evaluated over the period from 1975–
1976 to 1996. Th e median follow-up time from fi rst treatment to the most 
recent follow-up interview was 19 years. We detected 11 melanomas in 
nine patients during the follow-up time. One patient developed three pri-
mary melanomas. Th e detailed information is shown in Table 5.
Table 5 Patients with malignant melanoma in the PUVA follow-up study 1975-1996
Patient  Tumor  Skin Sex Age at No of  Time from Tumor
no no type  enrollment PUVA fi rst treatment location
       treatments to tumor, years
1 1 III F   65   55   2  foot
2 1 III M   47   284   7  upper left  calf
 2         284   17  ankle
 3         284   17  under 
               thumbnail
3 1 II M   41   46   10  upper back
4 1 III M   68   285   13  upper back
5 1 III M   60   138   16  upper 
               abdomen
6 1 III F   29   62   18  shoulder
7 1 III M   51   470   20  forehead
8 1 II M   54   52   20  back
9 1 II M   40   490   20   back
During the fi rst 15 years, the incidence of melanoma observed in 
the PUVA cohort was similar to that expected from the general popula-
tion. Beginning 15 years aft er the fi rst PUVA treatment, the incidence of 
melanoma in the PUVA cohort elevated signifi cantly and the highest in-
crease in the risk of melanoma was observed in patients who had received 
250 treatments or more during the years 1991 to 1996.
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In multivariate analysis, the number of PUVA treatments and time from 
the fi rst treatment gave the highest increase in the incidence of melanoma. 
Th e number of PUVA treatments and time from the fi rst treatment had a 
signifi cant association with the risk of melanoma (incidence rate ratio 4.1, 
95% CI=1.3–13.4 and 4.7, 95% CI=1.4–16.1, respectively). In particular, 
the increase in melanoma risk with the passage of time was striking. Dur-
ing the study, the rate increased from 19 per 100 000 person years to 32 per 
100 000 person years (the last fi gures for years 1991–1996).
Risk of noncutaneous malignant tumors in psoriasis 
patients treated with systemic PUVA therapy (study II)
During the follow up time (1975 or 1976 to 1996), 195 noncutaneous can-
cers developed in a cohort of 1380 patients. Th e overall risk of noncutanous 
cancer had not increased (RR=1.08, 95% CI=0.93–1.24). For the whole pe-
riod, the risk of thyroid cancer, breast cancer and central nervous system 
neoplasms was signifi cantly increased. Th e site specifi c RR with 95% CI 
are shown in Table 6. We examined the risk of cancer also by 10-year pe-
riods (1975–1986 and 1987–1996). Th e risk of breast cancer was elevated 
in both periods. For the central nervous system, the risk was not elevated 
for the latter period, whereas for thyroid cancer, the risk was signifi cantly 
increased only during the latter ten year period (RR=5.0, 95% CI=1.03–
14.61). We could not detect any association between higher levels of PUVA 
(over 300 treatments) and the risk of the aforementioned cancers.
Risk of noncutaneous malignant tumors in psoriasis patients treated 
with systemic PUVA therapy (study II)
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Table 6 Observed and expected number of noncutaneous cancer with RR and 95% CI 
in PUVA patients from 1975 to 1996 in patients in the PUVA follow-up study
Results
Site of cancer Observed (no.) Expected (no.) RR 95% CI
All sites 195 181.3 1.08 0.93–1.24
GI tract 45 37.4 1.20 0.88–1.61
Resp. tract 37 35.4 1.05 0.74–1.44
Breast 27 14.9 1.81 1.19–2.64
Female genitals 6 7.2 0.83 0.31–1.81
Male genitals* 24 35.7 0.67 0.43–1.00
Urinary tract 18 15.4 1.17 0.69–1.85
CNS 7 2.5 2.80 1.13–5.77
Th yroid 5 1.4 3.57 1.16–8.34
Lymphoma 6 6.8 0.88 0.32–1.92
Leukemia 6 4.6 1.30 0.48–2.84
Others 14   
* excludes squamous cell carcinoma of penis and scrotum
Persistent risk of nonmelanoma skin cancer in psoriasis 
patients treated with systemic PUVA therapy (study III)
Th is study evaluated the association of systemic PUVA treatments to the 
development of SCC and BCC in patients with psoriasis, who had discon-
tinued PUVA therapy long ago or were not substantially exposed to other 
carcinogens previously. Th e relative risk of SCC and BCC was elevated at 
every PUVA dose level. Th e risk of SCC was elevated more than that of 
BCC. Th e incidence of both squamous cell carcinoma and basal cell carci-
noma was more than three times higher aft er 1986 compared to that before 
1986. Th e total numbers for SCC was 375 versus 1047 and 221 versus 821 
for BCC respectively in those mentioned time intervals. Among patients 
who had at least 337 PUVA treatments, the risk of SCC during the last dec-
ade was over 100-fold compared to the normal population (RR=104, 95% 
CI=88.3–121.9). Th e higher risk of occurrence of tumours on anatomic 
sites other than head and neck suggested that PUVA was carcinogenic. 
Aft er year 1985 the risk of SCC increased fi vefold on the head and neck 
and 21-fold on the other parts of the body compared to that expected in 
the general population. In univariate analysis the role of PUVA, UVB, tar, 
methotrexate and ionising radiation on the development of SCC was as-
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sessed. Other exposures, except exposure to PUVA, did not have an impact 
to the risk of SCC. Among patients who did not develop SCC during the 
fi rst decade aft er the fi rst PUVA treatment, the level of exposure to PUVA 
was the most important risk factor for the development of SCC (RR=8.6, 
95% CI=4.9–15.2).
For BCC, the risk was substantially increased only in those patients who 
were exposed to high dose levels of PUVA (over 337 treatments). Th ey had 
a threefold increase in risk compared to those patients exposed to less than 
100 treatments. 
Risk of secondary cancers in patients with CTCL (study IV)
During the follow-up time (years 1953–1995), 319 patients with CTCL de-
veloped 36 subsequent primary cancers whereas the expected number in 
the normal population was 26 (SIR=1.4, 95% CI=1.0–1.9) (Table 7). Th e 
overall risk of lung cancer and lymphomas (Hodgkin’s and non-Hodg-
kin’s lymphoma combined) was increased (SIR=2.7, 95% CI=1.4–4.8 and 
SIR=7.0, 95% CI=1.9–18 respectively). Half of the histologic subtypes of 
lung cancer represented small- cell lung cancer. PUVA therapy did not ap-
pear have an infl uence on the cancers mentioned above because these can-
cers were detected in a range of 1 month to 2 years aft er the start of PUVA 
treatment. Also, some cancers were detected before PUVA was introduced 
as a clinical treatment. In nonmelanoma skin cancer, the SIR was 3.5 (95% 
CI=0.7–10). Th is fi nding was not signifi cant. During the observation pe-
riod, we also found a slight increase in the incidence of CTCL rising from 
0.65 to 1.75 during years 1961–1965 and 1976–1980, respectively.
Risk of secondary cancers in patients with CTCL (study IV)
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Table 7 Observed and expected number of subsequent cancer, with standardized inci-
dence ratio (SIR) and 95% confi dence interval (CI) with cutaneous T cell lymphoma 
(CTCL) from 1953–1995
Site of cancer Observed Expected SIR 95% CI
All sites 36 26 1.4 1.0–1.9
Stomach 3 2.4 1.3 0.3–3.7
Colon 1 1.4 0.7 0.0–3.9
Rectum 1 1.1 0.9 0.0–5.1
Biliary tract - 0.4 0.0 0.0–9.4
Pancreas - 1.1 0.0 0.0–3.4
Lung 12 4.4 2.7 1.4–4.8
Skin melanoma - 0.4 0.0 0.0–9.2
Nonmelanoma 
skin cancer 3 0.9 3.5 0.7–10
Kidney 1 0.8 1.3 0.0–7.2
Urinary tract, 
bladder 1 1.2 0.9 0.0–4.7
CNS 1 0.5 2.1 0.1–12
Hodgkin’s disease 2 0.1 21.0 2.6–77
Non-Hodgkin 
lymphoma 2 0.5 4.1 0.5–15
Myeloma - 0.4 0.0 0.0–10
Leukemia 2 0.6 3.3 0.4–12
Breast 4 1.8 2.3 0.6-5.8
Th yroid - 0.2 0.0 0.0–19
Risk of cancer in skin disease patients treated with 
cyclosporine (study V)
Th e overall risk for all cancers was not signifi cantly increased in skin dis-
ease patients (63 psoriasis, 96 atopic dermatitis, 73 palmoplantar pustu-
losis and 40 chronic hand eczema) treated with cyclosporine (SIR=1.31, 
95% CI=0.7–2.23). We found altogether 13 malignancies (Table 8). In 
men, we found an increased risk of all cancers in the age range 45–49 years 
(SIR=3.28; 95% CI=1.06–7.64). Th ese fi ve cancers were: brain tumor (as-
trocytoma), carsinoid tumor, mouth cancer and two prostate cancers. We 
did not found any squamous cell carcinomas, but we did detect three basal 
cell carcinomas. 
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Th e median treatment time with cyclosporine was eight months. Most 
of the thirteen patients (85%) who developed cancer had received medium 
dosage (2–4 mg/kg) cyclosporine treatment. In analysis of diff erent cov-
ariates we did not detect any correlation between phototherapy and these 
cancers (HR=0.98). Th e use of methotrexate was a protective factor to the 
development of subsequent cancer, but not signifi cant. In this study, the 
relative risk of cancer increased by 7 percent per year.
Th e SIR comparison between diff erent skin disease groups (atopic 
dermatitis, chronic hand eczema, palmoplantar pustulosis and psoriasis) 
showed a signifi cant increase in basal cell carcinomas in the psoriasis 
group (SIR=6.05, 95% CI=1.25–17.69). Th ere was no evidence that cy-
closporine was related to these basal cell carcinomas.
Table 8 Skin disease type, cancer type, duration of cyclosporine treatment and dosage in those 13 
patients who developed cancer during the follow-up (study V)
Skin disease   cancer type csa treatment  csa
     in months dosage
palmoplantar pustulosis breast cancer  5  low*
palmoplantar pustulosis MALT-lymphoma  12  low
palmoplantar pustulosis lung cancer **  14  medium
psoriasis  lung cancer **  2  medium
psoriasis  cervix cancer  8  medium
psoriasis  prostate cancer  30*** medium
psoriasis  carcinoid tumor  155 medium
atopic dermatitis  brain tumor   6  medium
  (astrocytoma)  
atopic dermatitis  prostate cancer  10  medium
atopic dermatitis  prostate cancer  19  medium
eczema  testis cancer  1,5  medium
eczema  mouth cancer  3  medium
eczema  brain tumor  3  medium  
  (meningeoma)   
* low indicates cyclosporine dosage under 2mg/kg, medium 2–4 mg/kg
** patient was a smoker
*** only this patient had received methotrexate treatment 
Risk of cancer in skin disease patients treated with cyclosporine (study V)
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Discussion
Possible methodological sources of error
In the Finnish Cancer Registry, the registration of malignancies is almost 
complete covering 99 per cent of all Finnish cancers (Teppo et al., 1994). 
Every solid cancer is registered separately. In nonmelanoma skin cancers, 
basal cell carcinoma is registered and reported separately and not counted 
to the overall cancer incidence (Karjalainen et al., 1989). Th e registration 
of both SCCs and BCCs is based in histopathological diagnosis. Allthough 
in study V we did not detect any SCCs, we had no reason to believe that 
this was an underestimation. It is highly unlikely that SCCs or BCCs in this 
study were reported less oft en than those in other population. Since the 
personal identifi cation numbers are used in the computerized record-link-
age procedure, technical inaccuracy is ruled out (Pukkala, 1992) (studies 
IV, V). 
Th e baseline incidence for melanoma, squamous and basal cell carcino-
mas and noncutaneous malignancies was obtained from the Surveillance, 
Epidemiology, and End Results (SEER) data (studies I, II). Th is database 
collects information of cancer from tumor registries of hospitals and pri-
vate laboratory records in certain regions of the USA, and covers samples 
of about 10 percent of the population (Miller et al., 1993). 
In studies I–III there has been criticism about the lack of control group 
of patients who had never received PUVA (Whitmore and Morison, 1997). 
PUVA treatment is an extremely effi  cient treatment in certain types of pso-
riasis. It is diffi  cult to desing a study where all patients had received exactly 
same treatments for psoriasis and the only diff erence being PUVA treat-
ment. 
General discussion
Th e increased dose-dependent risk of squamous cell carcinomas is a well 
documented side eff ect of systemic PUVA therapy. Th e capability of this 
treatment to induce pigmented lesions on the skin and nails (Rhodes et 
al., 1983b; Trattner et al., 1990) as well as its carcinogenic potential has 
raised the issue of the increased risk of melanoma among PUVA treated 
patients. In fact, PUVA lentigines are proliferations of melanocytes, which 
are comparable with freckles. Freckles are UV radiation induced clones 
of mutated melanocytes (Gilchrest, 1984; Kanerva et al., 1984), that are 
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associated with an increased risk of melanoma (Seykora and Elder, 1996; 
Pavlotsky et al., 1997). So far, the present American study (I) and its ex-
tension (Stern, 2001) are the only studies in which an increased risk of 
malignant melanoma has been detected in PUVA treated patients. Th is ad-
ditional follow-up reported seven new invasive melanomas till the end of 
1999. During the last 2.5 years, the incidence of melanomas increased to 
3.82 compared to 0.69 during all years (1975–1999) (Stern, 2001). Th ese 
additional fi ndings confi rm the signifi cance of study I.
During the fi rst 15 years, there was no increased risk of melanoma and 
the risk started to increase about 15 years aft er the fi rst treatment. During 
the years 1975–1990, four melanomas were detected, but from 1991–1996 
seven cases were found. In two previous large cohort studies of patients 
treated with PUVA, the average follow-up times have been seven and eight 
years, and this may be the reason that these studies failed to detect any 
increased melanoma risk (Henseler et al., 1987; Lindelöf et al., 1991). How-
ever, one of these studies has reported updated information aft er 16 years 
of follow-up, and yet no increase in the incidence of melanoma has been 
detected (Lindelöf et al., 1999). In this study, a fi ft h of the patients (total 
number 4799 patients) were treated with trimethylpsoralen bath + UVA, 
which is less carcinogenic than oral 8-methoxypsoralen (Hannuksela-
Svahn et al., 1999b). Our data ( I ) suggests that high levels of PUVA, over 
250 treatments, is a risk factor for the development of melanoma. Based on 
our results, it is not possible to determine the number of PUVA treatments 
at which the risk of melanoma starts to increase. It is possible that both a 
certain time (over 15 years) and high exposure to PUVA are needed at the 
same time to develop this increased risk.
Th e role of UVA in the development of melanoma is controversial. Epi-
demiological studies have shown that the incidence of melanoma does not 
have such a great latitudinal variation than that of SCC. Also, the latitudi-
nal variation of UVB is much greater than that of UVA (Armstrong and 
Kricker, 2001). Th e incidence rates of melanoma increase as the latitude 
decreases (Moan and Dahlback, 1992). Sunbeds and sun lamps emit mostly 
UVA radiation. A Swedish study reported an increased risk of melanoma 
in sunbed/sunlamp users (Westerdahl et al., 2000). Th ey showed that the 
risk of melanoma aft er tanning salon use was dose dependent and corre-
lated positively to the age of the customers sunlamps were fi rst used.
It is clear that UVA radiation can induce DNA damage in human cells 
(Marrot et al., 1999). Th ere is also evidence that UVA irradiation increases 
the frequency of melanoma metastases in the mouse model (Pastila and 
Leszczynski, 2005). A 12-fold increase in metastasis compared with UVA 
unexposed controls was detected. UVA irradiation also inducted low- met-
astatic potential melanoma cells to high- metastatic potential melanoma 
cells. In the fi sh model, UVA and visible spectral wavelengths were inter-
preted to be responsible for 90–95% of melanoma induction (Setlow et al., 
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1993). UVA had similar eff ects to melanocytes and keratinocytes, but UVB 
showed more pronounced eff ects on keratinocytes (Larsson et al., 2005). 
Th ese fi ndings may suggest that UVA irradiation has an important role 
in the development of melanoma. However, another mouse experiment 
showed that only UVB initiated melanoma in transgenic mice and the ef-
fect of UVA was comparable to a placebo (De Fabo et al., 2004). 
Clear risk factors for the development of melanoma are e.g., the number 
of pigmented nevi, skin type I–II, freckling and red or blond hair, previous 
skin burn, and dysplastic nevus syndrome (Kanzler and Mraz-Gernhard, 
2001; MacKie et al., 1989). In the present study (I), we did not have infor-
mation of the patients’ family history of melanoma or if they had dysplastic 
nevus syndrome. We do not know if the risk of melanoma was increased 
already at the beginning of the study. 
PUVA induced carcinogenesis is dependent on the total UVA dose. In 
study one (I), there is no knowledge of the total cumulative dose of UVA. 
Also, no burning history of these patients was available. However, BCC 
and malignant melanoma are both related to intensive sun burning. Pa-
tients in the PUVA follow up study did have only a modestly increased risk 
of BCC. Th is could be a refl ection that these patients perhaps did not have 
a serious burn history.
Th ere has been discussion about the diversity of melanomas arising on 
chronically sun exposed versus intermittently sun exposed areas. A recent 
study found diff erent genetic alterations in melanomas with diff erent levels 
of sun exposure (Curtin et al., 2005). Th is supports the previous suggestion 
that the response of melanocytes to UV light may be diff erent at diff erent 
sites of the body (Whiteman et al., 2003). Malignant melanoma is reported 
to occur more frequently on facial skin than on the body (Pearl and Scott, 
1986). Also, the clinical types can be diff erent: on the face lentigo maligna 
melanoma is the most common type. In our study (I), the lentigo maligna 
melanomas occurred in patients who had received the highest PUVA ex-
posure. Th is data was not published, because the diagnosis of melanoma 
subtypes was not able to be repeated reliably. Th ree cases were lentigo ma-
ligna melanomas, one was acral melanoma, three were nodular melano-
mas, three superfi cial spreading melanomas and one was unclassifi ed.
In the development of melanoma, intermittent extensive exposure to 
UV radiation is a risk factor and in that way BCC and melanoma resemble 
each other (Elwood, 1996). Melanocytes are very resistant to apoptosis. 
Th is has been explained by the high content of anti-apoptotic proteins, like 
Bcl-2, in melanocytes (Plettenberg et al., 1995). It it possible that UV ra-
diation induced resistence to apoptosis explains in part the relationship 
of melanoma risk to extensive, intermitted sun exposure (Gilchrest et al., 
1999). Some studies have speculated that sublethal, chronic exposure to 
UV radiation leads to an increased base level DNA repair capacity (Eller 
et al., 1994; Le et al., 1998). In the case of melanoma, because of the lack of 
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continuing exposure to UV radiation, the base line capacity to repair DNA 
is low resulting in retention of the mutated melanocytes and progression of 
melanoma (Gilchrest et al., 1999).
Th e use of UVB has increased in the PUVA follow-up study. However, 
in patients who developed melanoma, the exposure to high levels of UVB 
was no more frequent than in the cohort overall (I). Th is does not empha-
size the role of UVB in these melanomas.
Immunosuppression and UV radiation are both risk factors for the 
development of non-Hodgkin’s lymphoma (Fisher and Fisher, 2004). All-
though PUVA can have immunosuppressive eff ects, in the present study 
(II) long-term PUVA treatment was not associated with an overall in-
creased risk of noncutaneous cancer. In contrast to the data of nonmelan-
oma skin cancer risk in PUVA treated patients, this study (II) suggests that 
the carcinogenic eff ect of PUVA is limited to the skin. Th ere are later re-
ports of the increased risk of noncutaneous tumors in PUVA treated pa-
tients. In a Swedish study the risk of respiratory cancers was increased and 
in women the risk of kidney cancer was higher. Th e majority (64%) of these 
patients suff ered from psoriasis (Lindelöf et al., 1999). In our study (II), an 
increased risk for thyroid cancer, breast cancer and central nervous system 
cancer was detected. However, there was no association between the risk of 
any of these cancers and higher levels of exposure to PUVA. Finnish stud-
ies failed to show any increased overall incidence of noncutaneous cancers 
in patients treated with bath PUVA (Hannuksela et al., 1996; Hannuksela 
et al., 1999a; Hannuksela et al., 1999b). As to other possible risk factors 
other than UV irradiation, one of the fi ve thyroid cancer patients had re-
ceived ionizing radiation for treatment of psoriasis (II).
Th e increased risk of SCC associated to PUVA treatment was within 
the fi rst decade aft er starting PUVA (years 1979–1989) therapy more pro-
nounced in American studies than in European studies. In fact, fi rst in the 
beginning of 1990s the European Studies confi rmed the previous fi ndings 
from American studies of a dose-dependent increase of SCC (Lindelöf, 
1991; Brynzeel et al., 1991). Th e diff erences found may be due to a number 
of factors. Th e cumulative doses in American studies are higher than in 
European studies. In European studies the percentage of patients who had 
received over 1500J/cm2 of UVA varied from 9% to 13% (Ros et al., 1983; 
Tanew et al., 1986; Henseler et al., 1987). In American studies, a remark-
able higher percentage of patients exceeded this 1500 J/cm2 (Stern et al., 
1984; Forman et al., 1989). Also, in a Swedish study (Lindelöf et al., 1991), 
men exposed to doses greater than 1200 J/cm2 of UVA were 27.2 times 
more likely to have SCC than the general population. Th e baseline inci-
dence of SCC is higher in USA than in Europe, and this means the Euro-
pean studies require at least double of person years of follow-up to have the 
same power as the American studies.
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Most previous studies concerning the risk of nonmelanoma skin can-
cers deal with patients who are on active PUVA therapy. Based on stud-
ies done in organ transplant patients, the risk of SCC increases with the 
increasing dose of therapy of immunosuppressive therapy. Our study (I) 
showed that a long interval from the fi rst exposure to the development to 
melanoma is needed. In the PUVA follow-up study, the intensity of PUVA 
treatment has decreased. During the years 1975 to 1985 80% of the cumu-
lative PUVA was provided and aft er 1985 less than half (40%) of the origi-
nal 1380 patients still had PUVA exposure. However, the incidence of SCC 
and BCC increased aft er 1985. Th is was true in patients who did not have 
nonmelanoma skin cancer in the fi rst decade. Th e results (III) support the 
hypothesis that the carcinogenic risk of PUVA treatment is not restricted 
to patients with substantial previous exposure to carcinogens. Th e risk also 
remains high in patents who had stopped PUVA treatment. 
Narrow-band UVB treatment is a relatively new weapon in the photo-
therapy armament. In Finland, this treatment has been used since 1989 
(Karvonen et al., 1989). In study V, we did not separate whether our pa-
tients had received broad or narrow-band UVB. Initially, narrow-band 
UVB light sources were thought to be less carcinogenic than broad-band 
UVB (Cole et al., 1986). Th e narrow-band UVB light sources seem to be 
two to three times more carcinogenic if calculated per MED compared to 
broad- band light sources (de Gruilj et al., 1994). However, the cumula-
tive numbers of MED of narrow-band UVB irradiation needed to clear 
psoriasis is usually less than those required with broad-band UVB. Th is is 
in line with two recent studies. Weischer at al. conducted a study with 195 
psoriasis patients. Two thirds of the patients received narrow-band and 
one third broad- band UVB treatment. During a follow up of six years no 
nonmelanoma skin cancer was detected. One in situ melanoma was found 
within the same year that narrow-band phototherapy was started, and due 
to this short time-interval, treatment-related photocarcinogenesis can be 
ruled out in this case (Weischer et al., 2004). In another four year study of 
1908 patients treated with narrow-band UVB, no increased incidence of 
SCC or melanoma was found (Man et al., 2005). Th e increased incidence 
of BCC was speculated to be due to diagnostic bias. Also, in this study 
almost one third of BCCs were excised within three months from the start 
of treatment. 
Broad-band UVB treatment carries a theoretical risk of carcinogenesis, 
but epidemiological data on carcinogenity in humans has been shown to 
be only a moderate cancer risk related to UVB treatment. Larkö and Svan-
beck conducted a study with 85 psoriasis patients. All patients had received 
more than 100 UVB treatments. Two BCCs occurred in the psoriasis group 
and three SCCs in the control group, whereas there were no SCCs in the 
psoriasis patients. Th e diff erence between these two groups was not statis-
tically diff erent in terms of the total number of malignant lesions. Because 
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of the small sample size no convincing evidence of the carcinogenity of 
UVB treatment was obtained (Larkö and Svanbeck, 1982). In an American 
PUVA follow up study a fi ve -fold increase in the relative risk of SCC was 
detected (95% CI= 4.0–8.7), but UVB was not detected to be an indepen-
dent risk factor for the development of SCC (Stern et al., 1994). Lim and 
Stern have recently found that high UVB exposure (over 300 treatments) 
was signifi cantly associated with an increase in SCC in psoriasis patients 
(Lim and Stern, 2005). Among patients who had received low-dose PUVA 
treatment (under 100 treatments), high UVB exposure was not associated 
with the development of SCC and BCC on chronically sun- exposed sites 
like head and neck. 
Patients with the most common CTCL, mycosis fungoides, are treated 
with PUVA initially (Whittaker et al., 2003). CTCL patients with limited 
patch or plaque stage disease have close to normal life expectancy and usu-
ally get numerous PUVA treatments. In our clinic, we have seen mycosis 
fungoides patients developing SCC and BCC. We did not fi nd an increased 
risk of skin cancers. Th e three detected nonmelanoma skin cancers did 
not reach signifi cance. However, CTCL patients showed an increased risk 
of overall secondary cancer. Th e overall risk of lung cancer and lympho-
mas (Hodgkin and non-Hodgkin lymphomas combined together) had in-
creased. 
As CTCL is a disease of T lymphocytes, it could be speculated that 
natural cell mediated immune responses to transformed cells is decreased 
(Kantor et al., 1989). MF patients have decreased numbers of normal cir-
culating CD4+ T cells as a result of decreased synthesis of IFN-gamma, 
which results in decreased antitumor cytotoxic T lymphocyte activity. 
Th us, CTCL patients could have been more sensitive to the eff ect of immu-
nosuppressive treatments such as PUVA. In this study (IV), PUVA treat-
ment did not have any aff ect on the development of subsequent lung can-
cer or lymphomas. In a recently published study of the updated informa-
tion of the PUVA follow-up study, the risk of lymphomas was increased 
only in psoriasis patients who had received high dose methotrexate treat-
ment (Stern, 2006). It can be speculated that in CTCL compared to pso-
riasis patients the development of cancer is mediated through diff erent 
pathways. 
Th e incidence of CTCL is rising worldwide (Weinstock and Horm, 
1988; Hartge et al., 1994). Increased exposure to UV radiation has been 
speculated partly to explain this increase. p53 mutations are clearly linked 
to the development of SCC (Steele and Lane, 2005). One study has re-
ported p53 mutations in CTCLs (McGregor et al., 1999). Th ey found typi-
cal fi ngerprint mutations in tumour MF stage patients suggesting that 
UVB may play a role in the increased incidence of CTCL. Agaist this ar-
gues a large population based case- control study (Smedby, et al., 2005). 
Data analysis showed that high UV exposure was linked to reduced risk of 
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non-Hodgkin lymphoma. However, the history of skin cancer was associ-
ated with a two-fold increased risk of lymphomas. Th is suggests that the 
correlation between skin cancer and lymphomas is not mediated via UV 
exposure. In our study (IV), we did not detect any increase in the incidence 
of nonmelanoma skin cancers or melanoma. 
Study V did not show an increased risk of cancer among skin disease 
patients treated with cyclosporine. In this study, the majority of patients, 
two thirds, had some other infl ammatory skin disease than psoriasis. In an 
American study, the risk of squamous cell carcinoma was increased aft er 
any use of cyclosporine, but all patients had photochemotherapy treatment 
before (Marcel and Stern, 2001). A recent study by O’Donovan and col-
leagues presented a new possible mechanism for the development of skin 
cancers among organ transplant patients (O’Donovan et al., 2005). Th ey 
showed that azathioprine, another immunosuppressive agent, sensitizes 
DNA to UVA radiation. Th e metabolic end product of azathioprine is in-
corporated into the DNA of skin cells. With the presence of UVA radiation 
this metabolic end product turns into reactive oxygen species capable of 
damaging DNA. Th ey also made another interesting fi nding: the skin of 
patients treated with azathioprine became more sensitive to UVA but not 
to UVB during three months of observation. Marcil and Stern had a very 
similar setting in their study (Marcil and Stern, 2001): squamous cell car-
cinomas developed in patients who were exposed to PUVA previously and 
then treated with cyclosporine. Th ere have been speculations that it would 
be better to treat patients with PUVA therapy as late as possible in life and 
avoid the emergence of PUVA indused skin cancer by subsequent immu-
nosuppression like cyclosporine (Murphy, 1999). 
Renal transplant patients receiving a cyclosporine based regimen were 
at high risk for SCC but not for BCC (Glover et al., 1997). Th e use of cy-
closporine was an independent risk factor for development of neoplasms 
in another study (Marcen et al., 2003). Th us, the role of diff erent immuno-
suppressive treatments is controversial.
In study V, the median treatment time was 8 months and cyclosporine 
treatment was given intermittently. A previous European study found an 
increased risk of malignancies aft er an average of 1.9 years of cyclosporine 
treatment. All patients suff ered from psoriasis. Almost half of the malig-
nancies were nonmelanoma skin cancer (Paul et al., 2003). Th e diff erences 
between the results of these two previous studies (Marcil and Stern, 2001; 
Paul et al., 2005) and of study V are probably due to our short median 
treatment time and the relatively small proportion of psoriasis patients in 
the study (V). Th is study (V) is the fi rst one trying to evaluate the risk of 
cancer in cyclosporine treated patients including also other than psoriasis 
patients. We did not fi nd any evidence in this study (V) that short term 
cyclosporine treatment is a major risk factor for subsequent malignancy. 
With our sample size (272 patients) it was possible to exclude twofold in-
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cidence increase in cancer risk with a power of 90% and a two sided sig-
nifi cance lewel of 0.05 (Machin and Campbell, 1987). Our results are sup-
ported by Dantal et al. who found similar results in their study, where in 
kidney transplant patients there were signifi cantly less malignancies in the 
low-dose cyclosporine treatment group compared to those patients treated 
with normal doses (Dantal et al., 1998). Also, in a study conducted on 
rheumatoid arthritis patients and thus in patients with no previous history 
of phototherapy treatments, no increased risk of malignancies was found 
(van den Borne, et al., 1998).
Immunosuppression clearly predisposes to basal cell carcinoma. In or-
gan transplant patients and PUVA treated patients the normal ratio of BCC 
to SCC ratio is reversed (Stockfl eth et al., 2001; McKenna, 2004 ). Th is ratio 
has been reported to be approximately 4 to 1 in white persons in the United 
Kingdom and in Australia (Marks et al., 1993; Gray et al., 1997), and in 
Norway 6 to 1 (Henriksen et al., 1990). Th is ratio was 1 to 1.3 in organ 
transplant patients (Stockfl eth et al., 2001). In this study (V) we detected 
three basal cell carcinomas but no squamous cell carcinomas. 
In organ transplant patients, nonmelanoma skin cancers are mainly lo-
cated on sun exposed skin areas. Th is is associated with the amount of 
UV exposure (Bavink et al., 1993). Previous studies have shown that also 
in organ transplant patients the incidence of skin cancer increases as the 
latitude decreases (Bavink-Bouves et al., 1996; Jensen et al., 1999). Age at 
transplantation is associated with skin cancer risk (Ong et al., 1999) and 
that is assumed to be a refl ection of lifelong UV exposure. In our study (V), 
we did not detect any SCC and previous phototherapy did not have any 
infl uence to the cancers detected.
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Conclusions
Th is study was conducted to investigate the cancer risk related to immu-
nosuppressive treatments such as systemic PUVA and cyclosporine in dif-
ferent infl ammatory skin diseases. Based on the results presented in this 
thesis, the following conclusions can be drawn:
In psoriasis patients, the risk of malignant melanoma in PUVA treated 
patients is increased among patients who had received more than 250 treat-
ments or aft er 15 years of fi rst PUVA treatment. However, PUVA treatment 
does not increase the risk of noncutaneous cancers. Systemic PUVA treat-
ment increases the risk of SCC in a dose dependent manner especially in 
patients exposed to high dose PUVA.Th is risk is persistent even aft er sys-
temic PUVA treatment is stopped. Th e same trend is seen with BCC, but it 
is less pronounced.
In CTCL patients, the risk of developing secondary cancers was in-
creased. Of separate sites, the incidence of lung cancer and lymphomas was 
increased. Th ese patients did not have high exposure to PUVA treatments. 
Th e risk of SCCs was not increased.
In our study, we found no increased risk of cancer or particularly skin 
cancer in patients treated with short term cyclosporine and consisting 
mainly of other skin diseases (atopic dermatitis, palmoplantar pustulosis, 
chronic hand eczema) than psoriasis. In these patients, the relatively short 
term cyclosporine treatment without other previous immunosuppressive 
treatments is probably not associated with increased risk of cancer, but the 
size of our cohort was small.
In clinical practice, these fi ndings have led to a close and permanent 
follow-up of patients treated with systemic PUVA. 
Conclusions
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